Prescription drugs accounted for 11% of Medicare spending in 2010, but are expected to account for 20% of this budget by 2020. The purpose of this subproject is to advance our understanding of the use and efficiency of prescription drugs among Medicare beneficiaries. First, we characterize the use of pharmaceutical drugs in the U.S. Medicare population at the level of the region or physician-hospital network (PHN) into four categories depending on efficiency or effectiveness - that is, value per dollar spent. These range from the first category, highly effective, to the fourth category, drugs which could lead to adverse effects on health. In this and subsequent analyses, we will consider factors that may affect the efficiency of pharmaceutical use, such as care fragmentation, academic affiliation, health information technology adoption, market structure, and for some physicians, board scores from the American Board of Internal Medicine examinations. These measures can also be used across other subproject analyses, for example for PHNs in subproject 1 and regions in subproject 4. Second, we focus on pharmaceutical treatments for specific cohorts: myocardial infarction survivors, hip fracture survivors, and incident cases of chronic pulmonary disease. This focus allows us to adjust more easily for patient level factors and identify clearly effective treatments (e.g., clopidogrel following a drug-eluting stent). In later years, data will permit assessment of the impact of payment structure such as shared savings and partial capitation on prescription use measures. Third, we use the cohorts developed in the previous subsection to measure substitution effects, the extent to which spending wisely on highly effective pharmaceuticals may have positive effects on downstream healthcare costs, and conversely for those drugs with little known value (or even negative value). To adjust for differences across areas in underlying risk, we will draw on Project 5's risk adjustment measures. Finally, we describe differences in prescription drug use in population subgroups. Early work shows substantial differences in use of some effective medications among Medicare subgroups (e.g. Black, older, poor) compared to the population overall. In addition, we intend to study the under-65 Medicare population (largely those receiving Social Security Disability Insurance) where pharmaceutical treatment for mental illness is likely to be common.

Public Health Relevance

This subproject seeks to understand how variations across physician-hospital networks (PHNs) affect the health, quality of care, and health costs of the Medicare population. These findings could have first-order implications for measuring and improving pharmaceutical care across PHNs, as well as providing a better understanding of how drugs are used in actual clinical practice for, say, younger patients with mental illness or the very old, rather than those patients typically selected for randomized trials.

National Institute of Health (NIH)
National Institute on Aging (NIA)
Research Program Projects (P01)
Project #
Application #
Study Section
Special Emphasis Panel (ZAG1-ZIJ-1)
Project Start
Project End
Budget Start
Budget End
Support Year
Fiscal Year
Total Cost
Indirect Cost
Dartmouth College
United States
Zip Code
Norton, Edward C; Li, Jun; Das, Anup et al. (2018) Moneyball in Medicare. J Health Econ 61:259-273
Moen, Erika L; Kapadia, Nirav S; O'Malley, A James et al. (2018) Evaluating breast cancer care coordination at a rural National Cancer Institute Comprehensive Cancer Center using network analysis and geospatial methods. Cancer Epidemiol Biomarkers Prev :
Austin, Andrea M; Bynum, Julie P W; Maust, Donovan T et al. (2018) Long-Term Implications Of A Short-Term Policy: Redacting Substance Abuse Data. Health Aff (Millwood) 37:975-979
Likosky, Donald S; Sukul, Devraj; Seth, Milan et al. (2018) Association Between Medicaid Expansion and Cardiovascular Interventions in Michigan. J Am Coll Cardiol 71:1050-1051
Bekelis, Kimon; Chang, Chiang-Hua; Malenka, David et al. (2018) Direct oral anticoagulant and antiplatelet combination therapy: Hemorrhagic events in coronary artery stent recipients. J Clin Neurosci 50:24-29
Kelley, Amy S; Bollens-Lund, Evan; Covinsky, Kenneth E et al. (2018) Prospective Identification of Patients at Risk for Unwarranted Variation in Treatment. J Palliat Med 21:44-54
Bekelis, Kimon; Missios, Symeon; Shu, Joel et al. (2018) Surgical outcomes for patients diagnosed with dementia: A coarsened exact matching study. J Clin Neurosci 53:160-164
Bekelis, Kimon; Missios, Symeon; Coy, Shannon et al. (2018) Association of Hospital Teaching Status with Neurosurgical Outcomes: An Instrumental Variable Analysis. World Neurosurg 110:e689-e698
Missios, Symeon; Bekelis, Kimon (2018) Association of Hospitalization for Neurosurgical Operations in Magnet Hospitals With Mortality and Length of Stay. Neurosurgery 82:372-377
Ouayogodé, Mariétou H; Meara, Ellen; Chang, Chiang-Hua et al. (2018) Forgotten patients: ACO attribution omits those with low service use and the dying. Am J Manag Care 24:e207-e215

Showing the most recent 10 out of 263 publications